Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-d-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?

Thyroid

Volumn 20, Issue 1, 2010, Pages 15-23

  Vera, Pierre ^a,b   Kuhn Lansoy, Caroline ^a   Edet Sanson, Agathe ^a,b   Hapdey, Sebastien ^a,b   Modzelewski, Romain ^a,b   Hitzel, Anne ^a   D'Anjou, Joelle ^c   Basuyau, Jean Pierre ^d  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c Department of Pathology ^*  (France)

^d CENTRE HENRI BECQUEREL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER SIZE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE COURSE; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRESCHOOL CHILD; PRIORITY JOURNAL; RECURRENT CANCER; SCHOOL CHILD; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY; WHOLE BODY SCINTISCANNING;

ADENOCARCINOMA, FOLLICULAR; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PAPILLARY; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORODEOXYGLUCOSE F18; HORMONE REPLACEMENT THERAPY; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RECOMBINANT PROTEINS; THYROGLOBULIN; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; THYROXINE; YOUNG ADULT;

EID: 75149119681     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2008.0416     Document Type: Article

References (42)

1. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sanchez FF, Toft A, Wiersinga WM 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. Eur J Endocrinol 150:105-112. (Pubitemid 38312801)
2. Pacini F, Schlumberger M, Harmer C, Berg GG, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Reiners C, Sanchez FF, Smit J, Wiersinga W 2005 Post-surgical use of radioiodine (131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651-659.
3. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109-142.
4. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092-4097.
5. Schlumberger M, Arcangioli O, Piekarski JD, Tubiana M, Parmentier C 1988 Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 29:1790-1794.
6. Schluter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M 2001 Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J Nucl Med 42:71-76.
7. Shammas A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N 2007 18F-FDG PET=CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J Nucl Med 48:221-226.
8. Moog F, Linke R, Manthey N, Tiling R, Knesewitsch P, Tatsch K, Hahn K 2000 Influence of thyroid-stimulating hormone levels on uptake of FDG in recurrent and metastatic differentiated thyroid carcinoma. J Nucl Med 41:1989-1995.
9. Filetti S, Damante G, Foti D 1987 Thyrotropin stimulates glucose transport in cultured rat thyroid cells. Endocrinology 120:2576-2581.
10. Hosaka Y, Tawata M, Kurihara A, Ohtaka M, Endo T, Onaya T 1992 The regulation of two distinct glucose transporter (GLUT1 and GLUT4) gene expressions in cultured rat thyroid cells by thyrotropin. Endocrinology 131:159-165.
11. Russo D, Damante G, Foti D, Costante G, Filetti S 1994 Different molecular mechanisms are involved in the multihormonal control of glucose transport in FRTL5 rat thyroid cells. J Endocrinol Invest 17:323-327.
12. Petrich T, Borner AR, Otto D, Hofmann M, Knapp WH 2002 Influence of rhTSH on [(18)F]fluorodeoxyglucose uptake by differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 29:641-647.
13. Chin BB, Patel P, Cohade C, Ewertz M, Wahl R, Ladenson P 2004 Recombinant human thyrotropin stimulation of fluoro-D-glucose positron emission tomography uptake in welldifferentiated thyroid carcinoma. J Clin Endocrinol Metab 89:91-95.
14. Al Nahhas A, Khan S, Gogbashian A, Banti E, Rampin L, Rubello D 2008 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy. In Vivo 22:109-114 (review).
15. Lind P, Kohlfurst S 2006 Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer. Semin NuclMed 36:194-205.
16. Nanni C, Rubello D, Fanti S, Farsad M, Ambrosini V, Rampin L, Banti E, Carpi A, Muzzio P, Franchi R 2006 Role of 18F-FDG-PET and PET=CT imaging in thyroid cancer. Biomed Pharmacother 60:409-413.
17. Reske SN, Kotzerke J 2001 FDG-PET for clinical use. Results of the 3rd German Interdisciplinary Consensus Conference, "Onko-PET III", 21 July and 19 September 2000. Eur J Nucl Med 28:1707-1723.
18. Schoder H, Yeung HW 2004 Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 34:180-197.
19. Jabour BA, Choi Y, Hoh CK, Rege SD, Soong JC, Lufkin RB, Hanafee WN, Maddahi J, Chaiken L, Bailet J 1993 Extracranial head and neck: PET imaging with 2-[F-18]fluoro-2-deoxy-D-glucose and MR imaging correlation. Radiology 186:27-35.
20. Grunwald F, Briele B, Biersack HJ 1999 Non-131Iscintigraphy in the treatment and follow-up of thyroid cancer. Single-photon-emitters or FDG-PET? Q J Nucl Med 43:195-206.
21. Iwata M, Kasagi K, Misaki T, Matsumoto K, Iida Y, Ishimori T, Nakamoto Y, Higashi T, Saga T, Konishi J 2004 Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer. Eur J Nucl Med Mol Imaging 31:491-498.
22. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY 1999 Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. J Nucl Med 40:986-992.
23. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A 2001 Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42:1464-1469.
24. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ 2000 Prognostic value of [18F] fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J Clin Endocrinol Metab 85:1107-1113.
25. Mirallié E, Guillan T, Bridji B, Resche I, Rousseau C, Ansquer C, Bodet-Milin C, Curtet C, Carnaille B, Murat A, Charbonnel B, Kraeber-Bodere F 2007 Therapeutic impact of 18FDG-PET=CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma. Surgery 142:952-958.
26. Schluter B, Grimm-Riepe C, Beyer W, Lubeck M, Schirren-Bumann K, Clausen M 1998 Histological verification of positive fluorine-18 fluorodeoxyglucose findings in patients with differentiated thyroid cancer. Langenbecks Arch Surg 383:187-189.
27. Saab G, Driedger AA, Pavlosky W, McDonald T, Wong CY, Yoo J, Urbain JL 2006 Thyroid-stimulating hormonestimulated fused positron emission tomography=computed tomography in the evaluation of recurrence in 131I-negative papillary thyroid carcinoma. Thyroid 16:267-272.
28. van Tol KM, Jager PL, Piers DA, Pruim J, de Vries EG, Dullaart RP, Links TP 2002 Better yield of (18)fluorodeoxyglucose-positron emission tomography in patients with metastatic differentiated thyroid carcinoma during thyrotropin stimulation. Thyroid 12:381-387.
29. Hooft L, van der Veldt AA, van Diest PJ, Hoekstra OS, Berkhof J, Teule GJ, Molthoff CF 2005 [18F]fluorodeoxyglucose uptake in recurrent thyroid cancer is related to hexokinase I expression in the primary tumor. J Clin Endocrinol Metab 90:328-334.
30. Feine U 1998 Fluor-18-deoxyglucose positron emission tomography in differentiated thyroid cancer. Eur J Endocrinol 138:492-496.
31. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H 1997 Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. Eur J Nucl Med 24:1342-1348.
32. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ 1999 [18F]-2-fluoro-2-deoxy-dglucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291-2302.
33. Grunwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, Schober O, Lerch H, Brandt-Mainz K, Burchert W, Hiltermann G, Cremerius U, Biersack HJ 1999 Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 26:1547-1552.
34. Muros MA, Llamas-Elvira JM, Ramirez-Navarro A, Gomez MJ, Rodriguez-Fernandez A, Muros T, Lopez dlT, Becerra A, Carreras JL 2000 Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels. Am J Surg 179:457-461.
35. Frilling A, Tecklenborg K, Gorges R, Weber F, Clausen M, Broelsch EC 2001 Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma. Ann Surg 234:804-811.
36. Lind P, Kresnik E, Kumnig G, Gallowitsch HJ, Igerc I, Matschnig S, Gomez I 2003 18F-FDG-PET in the follow-up of thyroid cancer. Acta Med Austriaca 30:17-21.
37. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP 2005 The role of positron emission tomography=computed tomography in the management of recurrent papillary thyroid carcinoma. Laryngoscope 115:237-243.
38. Ong SC, Ng DC, Sundram FX 2005 Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography=computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans. Singapore Med J 46:297-301.
39. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U 2006 Integrated PET=CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47:616-624.
40. Iagaru A, Kalinyak JE, McDougall IR 2007 F-18 FDG PET=CT in the management of thyroid cancer. Clin Nucl Med 32:690-695.
41. Freudenberg LS, Frilling A, Kuhl H, Muller SP, Jentzen W, Bockisch A, Antoch G 2007 Dual-modality FDG-PET=CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer. Eur Radiol 17:3139-3147.
42. Zuijdwijk MD, Vogel WV, Corstens FH, Oyen WJ 2008 Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. Nucl Med Commun 29:636-641.